New Economy Portfolio Update..Looking to buy a stock with a solid catalyst on Oct 1st which is closing in on the next 60 days.
Alert..bought starter in PBMD in New Economy Portfolio at $3.00 for their catalyst on Oct 1st. Shares are a challenge to grab. Increased volume will allow for closer & more reasonable ask/bids on level 2 as the company definitely has the shares O/S to allow for solid trading liquidity. Underfollowed company.
Market Cap is 109M. 30m in cash with zero debt. 32m in float & 35m O/S. Avg 3m volume is 10K. Avg 10 day volume is 15K. 52wk low is $1.70 and 52wk high is $6.96.
PBMD- Prima Biomed Feb 2013 Presentation: http://bit.ly/155mFzu From thewallstreetanalyzer.com: CEO Interview http://bit.ly/17Qq835 2:50 of interview is catalyst discussion!
CAN-003 abstract accepted for oral presentation at the European Cancer Congress in Amsterdam. Dr. Jeffrey Goh, the lead author, will deliver an oral presentation of top-line results from the CAN-003 trial during the Gynecological Cancer session that starts at 9:00am, Central European Time, on October 1, 2013. CAN-003 is a 63-patient study of CVac for the maintenance treatment of epithelial ovarian cancer patients in remission. The CAN-003 results will be important to help inform the ongoing clinical development of CVac for ovarian cancer.
News 
Market Data 
Discover 
AI
